Design and development of an RNAi therapeutic (DFP-10825) for intracoelomic injection to treat refractory cancers

Abstract

RNA interference (RNAi) therapeutic, a nucleic acid medicine that can downregulate the target-gene expression specifically, attracts a great deal of attention more than ever, because of the market of patisiran (Onpattro^®) in 2018, a first RNAi drug in the world. We recently developed a novel RNAi therapeutic for intracoelomic injection. A coelomic cavity, including pleural cavity and peritoneal cavity, is a common site for the development of several refractory cancers, e.g. malignant pleural mesothelioma and peritoneal disseminated metastasis for cancer, which is poorly responsive to conventional systemic chemotherapy. In this topic, we review the therapeutic efficacy of our intracoelomic RNAi therapeutic (DFP-10825) for the treatment of refractory cancers developed in coelomic cavity.